DK0981618T3 - Anti-Apo-2-antistof - Google Patents

Anti-Apo-2-antistof

Info

Publication number
DK0981618T3
DK0981618T3 DK98926036T DK98926036T DK0981618T3 DK 0981618 T3 DK0981618 T3 DK 0981618T3 DK 98926036 T DK98926036 T DK 98926036T DK 98926036 T DK98926036 T DK 98926036T DK 0981618 T3 DK0981618 T3 DK 0981618T3
Authority
DK
Denmark
Prior art keywords
apo
antibody
chimeras
antibodies
nucleic acid
Prior art date
Application number
DK98926036T
Other languages
English (en)
Other versions
DK0981618T4 (da
Inventor
Avi J Ashkenazi
Camellia W Adams
Anan Chuntharapai
Kyung Jin Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26693808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0981618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK0981618T3 publication Critical patent/DK0981618T3/da
Application granted granted Critical
Publication of DK0981618T4 publication Critical patent/DK0981618T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98926036.9T 1997-05-15 1998-05-14 Anti-Apo-2-antistof DK0981618T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85721697A 1997-05-15 1997-05-15
US2074698A 1998-02-09 1998-02-09
PCT/US1998/009704 WO1998051793A1 (en) 1997-05-15 1998-05-14 Apo-2 RECEPTOR

Publications (2)

Publication Number Publication Date
DK0981618T3 true DK0981618T3 (da) 2007-11-26
DK0981618T4 DK0981618T4 (da) 2011-11-21

Family

ID=26693808

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98926036.9T DK0981618T4 (da) 1997-05-15 1998-05-14 Anti-Apo-2-antistof
DK07002962.4T DK1860187T3 (da) 1997-05-15 1998-05-14 Apo-2-receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07002962.4T DK1860187T3 (da) 1997-05-15 1998-05-14 Apo-2-receptor

Country Status (12)

Country Link
US (1) US20030017161A1 (da)
EP (2) EP0981618B2 (da)
JP (3) JP2001511653A (da)
AT (2) ATE516354T1 (da)
CA (1) CA2287911C (da)
CY (1) CY1106966T1 (da)
DE (1) DE69838249T3 (da)
DK (2) DK0981618T4 (da)
ES (1) ES2293682T5 (da)
IL (1) IL132067A0 (da)
PT (2) PT1860187E (da)
WO (1) WO1998051793A1 (da)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
JP4330180B2 (ja) * 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
ATE443723T1 (de) * 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
EP1181319B1 (en) * 1999-05-28 2009-04-22 Genentech, Inc. Chimeric dr4 antibodies and uses thereof
ATE330972T1 (de) * 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
CN101633692A (zh) 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
CA2384762A1 (en) * 1999-09-15 2001-03-22 Genentech, Inc. Apo-2 receptor antibodies
MXPA02007787A (es) * 2000-02-11 2004-09-10 Inst Genetics Llc Moleculas trade y uso relacionado con las mismas.
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
DE60136816D1 (de) 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7064189B2 (en) * 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
EP1409544B1 (en) 2001-07-03 2009-06-17 Genentech, Inc. Human dr4 antibodies and uses thereof
EP1501866A4 (en) 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
US20080199423A1 (en) * 2004-06-18 2008-08-21 Genentech, Inc. Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
MX2007001469A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200706246B (en) * 2005-02-02 2008-11-26 Genentech Inc DR5 antibodies and uses thereof
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5562521B2 (ja) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
CN101287990B (zh) 2005-08-16 2012-07-04 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
CA2631327C (en) 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
RU2474585C2 (ru) 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
ES2533266T5 (es) 2007-10-30 2018-04-18 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
BRPI0823046B1 (pt) 2008-08-14 2021-12-14 Genentech, Inc Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
JP2012504969A (ja) 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
JP2012511929A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン 攪拌タンク反応器及び方法
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
SI2473617T1 (sl) 2009-09-01 2020-07-31 F. Hoffmann-La Roche Ag Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
EP2550018B1 (en) 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Compositions and methods useful for stabilizing protein-containing formulations
WO2011118739A1 (ja) 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
WO2011146394A1 (en) 2010-05-17 2011-11-24 Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
US20130130317A1 (en) 2010-08-02 2013-05-23 Kyowa Hakko Kirin Co., Ltd Method for producing substance
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
PH12013500845A1 (en) 2010-10-29 2013-06-24 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
EP2653540B9 (en) 2010-12-15 2018-05-16 Inter-University Research Institute Corporation Research Organization of Information and Systems Protein production method
WO2012091023A1 (ja) 2010-12-27 2012-07-05 協和発酵キリン株式会社 培地およびキレート剤を含む水溶液の調製方法
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
US20130012689A1 (en) 2011-07-08 2013-01-10 Emd Millipore Corporation Depth Filters For Disposable Biotechnological Processes
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
BR112014023176B1 (pt) 2012-03-27 2021-09-28 Genentech, Inc. Métodos de produção de uma proteína recombinante
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
CA2898146C (en) 2012-12-19 2020-12-01 Charles Andrew BOSWELL Methods and compositions for radiohalogen protein labeling
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
AU2015287760B2 (en) 2014-07-09 2019-06-20 Genentech, Inc. pH adjustment to improve thaw recovery of cell banks
US10849912B2 (en) 2016-02-09 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
EP3436610A1 (en) 2016-03-29 2019-02-06 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
EP3323428A1 (en) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
HRP20240584T1 (hr) 2018-07-03 2024-07-19 Bristol-Myers Squibb Company Postupak proizvodnje rekombinantnih proteina
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
EP3875595A4 (en) 2018-11-02 2022-07-13 Kyowa Kirin Co., Ltd. Liquid medium preparation method
TWI856084B (zh) 2019-04-01 2024-09-21 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
EP3953380A4 (en) 2019-04-12 2023-01-25 Geltor, Inc. RECOMBINATION ELASTIN AND ASSOCIATED PRODUCTION
EP4007808A1 (en) 2019-08-01 2022-06-08 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
EP4071167A4 (en) 2019-12-03 2024-03-06 Shanghai Jiao Tong University School of Medicine ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5153118A (en) * 1985-12-17 1992-10-06 Eastern Virginia Medical Authority Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
WO1989003397A1 (en) * 1987-10-16 1989-04-20 Biomedical Systems Limited Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
US5216126A (en) * 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
JP4330180B2 (ja) * 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
AU7126498A (en) * 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
CA2301202A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
US20030017161A1 (en) 2003-01-23
JP2001511653A (ja) 2001-08-14
WO1998051793A1 (en) 1998-11-19
JP2010075184A (ja) 2010-04-08
IL132067A0 (en) 2001-03-19
EP0981618A1 (en) 2000-03-01
DE69838249T3 (de) 2012-01-19
EP0981618B1 (en) 2007-08-15
ATE370232T1 (de) 2007-09-15
AU7796398A (en) 1998-12-08
PT981618E (pt) 2007-11-23
HK1109423A1 (en) 2008-06-06
JP2008148695A (ja) 2008-07-03
ES2293682T5 (es) 2011-11-17
DK1860187T3 (da) 2011-10-31
DE69838249D1 (de) 2007-09-27
DK0981618T4 (da) 2011-11-21
AU740858B2 (en) 2001-11-15
ATE516354T1 (de) 2011-07-15
DE69838249T2 (de) 2008-05-15
CA2287911A1 (en) 1998-11-19
EP0981618B2 (en) 2011-08-24
ES2293682T3 (es) 2008-03-16
EP1860187A1 (en) 2007-11-28
CY1106966T1 (el) 2012-09-26
PT1860187E (pt) 2011-10-04
CA2287911C (en) 2014-05-06
EP1860187B1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
DK0981618T3 (da) Anti-Apo-2-antistof
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
ATE500323T1 (de) Subtilisin-variante
DK1095140T3 (da) Neurotrofe faktorer
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
TR199900903T2 (xx) Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DK1009817T3 (da) RTD-receptor
WO2004043403A3 (en) Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
WO2001019861A3 (en) Apo-2 receptor antibodies
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
SE9602822D0 (sv) New receptor
DK0708831T3 (da) Celletæthedsforstærkende proteintyrosinphosphataser
FI971086A7 (fi) Kinaasia sitova proteiini ja sen käyttö
SE9604439D0 (sv) New receptor
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
DE69827532D1 (de) Polypeptide und dafür kodierende Nukleinsäure
DE69829417D1 (de) Polypeptide und dafür kodierende Nukleinsäure